Athersys Inc: (NASD: ATHX)

$2.12

0.06 (2.91%)

Volume 606,168

May 14 04:00 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.27%
#2	Buy	18.43%
#3	Hold	9.86%
#4	Sell	4.09%
#5	Strong Sell	1.87%
S&P	500	9.59%

Overview Quote

            Stock Activity
        
		Day Low - High
		2.07 - 2.16
	
		52wk Low - High
		0.95 - 2.42
	
		Previous Close
		2.06
	
		Avg. Volume
		1,096,544
	
		Industry
		MED-BIOMED/GENE
	
		Market Cap
		110.23 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		1.76
	
		PE (Forward)
		0.00
	
		Current Year Est.
		-0.43
	
		Quarterly Earnings ESP 
		NA
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.27%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.43%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        9.86%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.09%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        1.87%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.59%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Outperform
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		79 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/10/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            NA
                        
                            PEG Ratio
                            NA
                        
                            Current Year Est.
                            -0.43
                        
                            Current Quarter Estimate
                            -0.10
                        
                            Most Accurate Estimate
                            NA
                        
                            Earnings ESP 
                            NA
                        
                            Next Earnings Report Date
                            05-14-2013
                        
                            EPS Last Year
                            -0.51
                        
                            Expected Earnings Growth
                            NA
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is also developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). Athersys is developing MultiStem(r), its patented, adult-derived ``off the shelf'' stem cell product platform, for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications.   
Full ATHX Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
ATHX Chart  by YCharts

Earnings Estimates

	Current Qtr (03/2013)	Next Qtr (06/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	-0.10	-0.11	-0.43	-0.29
Number of Estimates	1	1	2	1
Low Estimate	-0.10	-0.11	-0.48	-0.29
High Estimate	-0.10	-0.11	-0.38	NA
Year Ago EPS	-0.17	-0.13	-0.52	-0.43
EPS Growth	41.18%	15.38%	17.31%	32.56%

More ATHX Estimates

Average Earnings Estimates for ATHX

EPS Growth for ATHX

Industry Analysis

Name	Symbol	Previous Close
ATHERSYS INC	ATHX	2.06
AETERNA ZENTARS	AEZS	1.87
ANIKA THERAPEUT	ANIK	13.90
GENTIUM SPA-ADR	GENT	8.31
NOVELOS THERAPT	NVLT	0.44
AASTROM BIOSCI	ASTM	0.60
ACHILLION PHARM	ACHN	7.25
AFFYMAX INC	AFFY	1.31
ALEXION PHARMA	ALXN	104.86
ALKERMES INC	ALKS	31.47

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Zacks Commentary

Elan in Royalty Deal with THRX

May 14, 2013

Celgene Attains 52-Week High

May 14, 2013

Spectrum Pharma Reports 1Q Loss

May 14, 2013

Glaxo/THRX's Breo Ellipta Gets FDA Nod

May 13, 2013

PDL BioPharma Misses Earnings Ests

May 13, 2013

Medivation Loss Narrower Than Expected

May 13, 2013

Disappointing 1Q Earnings for IART

May 10, 2013

Dendreon Narrows 1Q Loss

May 10, 2013

More ATHX Zacks Commentary

Financials

EPS TTM	-0.51
Sales	9
Net Income	-15
Price/Earnings	NA
Price/Book	5.40
Price/Cash Flow	NA
Price/Sales	12.66

More ATHX Financials

News

Athersys Reports First Quarter 2013 Results - Globenewswire

May 14, 2013

Earnings Scheduled For May 14, 2013 - Benzinga

May 14, 2013

Position Yourself for Big Returns in the Stem Cell Space: Jason Kolbert - Kapitall

May 10, 2013

Safe Stem Cell Therapy for Healing Is Still a Strong Bet - TheMotleyFool

May 7, 2013

Negative Opinion on AVEO/ALPMY Candidate - Zacks.Com

May 4, 2013

Athersys receives MHRA approval to expand Phase II ischemic stroke study - Datamonitor

Apr 26, 2013

Athersys to Present at 12th Annual Needham Healthcare Conference - Globenewswire

Apr 25, 2013

Athersys Down 7.6%, Shares Slide into the Red (ATHX) - Financial News Network Online - Market Movers

Apr 19, 2013

See All News Stories on ATHX

Broker Recommendations

Current ABR	1.00
ABR (Last Week)	1.00
# of recs in ABR	2
Average Target Price	4.00
Industry Rank by ABR	79 out of 265
Rank in Industry	38 out of 155

More ATHX Broker Recommendations

Day Low - High	2.07 - 2.16
52wk Low - High	0.95 - 2.42
Previous Close	2.06
Avg. Volume	1,096,544
Industry	MED-BIOMED/GENE
Market Cap	110.23 M
Div - Yield	0.00 - 0.00
Beta	1.76
PE (Forward)	0.00
Current Year Est.	-0.43
Quarterly Earnings ESP	NA

PE (Forward)	NA
PEG Ratio	NA
Current Year Est.	-0.43
Current Quarter Estimate	-0.10
Most Accurate Estimate	NA
Earnings ESP	NA
Next Earnings Report Date	05-14-2013
EPS Last Year	-0.51
Expected Earnings Growth	NA

Username: Password:

Remember me [?]

Athersys Inc: (NASD: ATHX)

$2.12

0.06 (2.91%)

Volume 606,168

May 14 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-BIOMED/GENE

Zacks Commentary

Financials

News

Broker Recommendations